


MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Medical Outsourcing Solutions</p> <p>2. 1735 DeKalb Ave. Sycamore, IL 60178</p>	<p>In accordance with application dated January 28, 2021,</p>	<p>4. Expiration Date: August 31, 2025</p>
	<p>3. License No.: 12-35254-01 is amended in its entirety to read as follows:</p>	<p>5. Docket No.: 030-38851 Reference No.:</p>
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>9. Authorized use</p> <p>A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.</p> <p>B. For use in imaging and localization studies permitted by 10 CFR 35.200.</p>



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 12-35254-01

Docket or Reference No.:
030-38851

Amendment No. 10

CONDITIONS

10. Licensed material listed in Subitem Nos. 6.A. and 6.B. shall be used at the licensee's facilities located at:
- A. Greene County General Hospital, 1185 N 1000 W, Linton, Indiana, 47441
 - B. Deaconess Gibson Hospital, 1808 Sherman Dr., Princeton, Indiana, 47670
 - C. Sullivan Community Hospital, 2200 N Section St., Sullivan, Indiana, 47882
 - D. Barton County Memorial Hospital, 29 NW 1st Ln., Lamar, Missouri, 64759
11. The Radiation Safety Officer (RSO) for this license is William S. Gooch.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
 - B. The following individuals are authorized users for the material and medical uses as indicated:

<u>Authorized User (M.D., D.O., etc.)</u>	<u>Material and Use</u>
David M. Ayoub, M.D.	10 CFR 35.100, 10 CFR 35.200
John L. Bormann, M.D.	10 CFR 35.100, 10 CFR 35.200
Jacob Eitel, M.D.	10 CFR 35.100, 10 CFR 35.200
Joseph R. England, M.D.	10 CFR 35.100, 10 CFR 35.200
Tom Fielder, M.D.	10 CFR 35.100, 10 CFR 35.200
Geoffrey Geoghegan, M.D.	10 CFR 35.100, 10 CFR 35.200
Reynaldo N. Gonzales, M.D.	10 CFR 35.100, 10 CFR 35.200
Chester E. Harrison, M.D.	10 CFR 35.100
Jeffrey B. Hemmerlein, M.D.	10 CFR 35.100, 10 CFR 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 12-35254-01

Docket or Reference No.:
030-38851

Amendment No. 10

Authorized User (M.D.,D.O.,etc.)Material and Use

Lee E. Hoagland, M.D.	10 CFR 35.100,10 CFR 35.200
Mark Adam Hubbard, M.D.	10 CFR 35.100,10 CFR 35.200
Shawn Johnson, M.D.	10 CFR 35.100,10 CFR 35.200
Robert R. Knudson, M.D.	10 CFR 35.100,10 CFR 35.200
Joseph B. Lee, D.O.	10 CFR 35.100,10 CFR 35.200
Sanjev Makhecha, D.O.	10 CFR 35.100,10 CFR 35.200
William Mason, M.D.	10 CFR 35.100,10 CFR 35.200
James D. McDaniel, M.D.	10 CFR 35.100,10 CFR 35.200
Benjamin Meyer, M.D.	10 CFR 35.100,10 CFR 35.200
Ryan D. Meyer, M.D.	10 CFR 35.100,10 CFR 35.200
Janine E. Morris, M.D.	10 CFR 35.100,10 CFR 35.200
J. Michael Neahring, M.D.	10 CFR 35.100,10 CFR 35.200
Thomas E. Schultheis, M.D.	10 CFR 35.100,10 CFR 35.200
Curtis C. Stautz, M.D.	10 CFR 35.100,10 CFR 35.200
Andre Byard Stovall, M.D.	10 CFR 35.100,10 CFR 35.200
David M. Sullivan, M.D.	10 CFR 35.100,10 CFR 35.200
John P. Sutkowski, M.D.	10 CFR 35.100,10 CFR 35.200
Killol J. Thakore, M.D.	10 CFR 35.100,10 CFR 35.200
Craig A. Triola, M.D.	10 CFR 35.100,10 CFR 35.200
Robert A. Vogt, M.D.	10 CFR 35.100,10 CFR 35.200
Daniel W. Whitehead, M.D.	10 CFR 35.100,10 CFR 35.200
Kenneth William Winkler, M.D.	10 CFR 35.100,10 CFR 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 12-35254-01

Docket or Reference No.:
030-38851

Amendment No. 10

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those statements, representations, and procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence impose on the licensee requirements that are more restrictive than or in addition to the regulations.
- A. Application dated June 26, 2015 (ML15182A362)
 - B. Letter dated July 20, 2015 (ML15202A118)
 - C. Letter dated September 10, 2015 (ML15272A440)
 - D. Letter dated April 26, 2017 (ML17122A152)
 - E. Letter dated May 10, 2017 (ML17163A043)
 - F. Letter dated June 7, 2017 (ML17159A821)
 - G. Letter dated July 11, 2017 (ML17192A467)
 - H. Letter dated October 10, 2018 limited to addition of Sullivan Community Hospital facilities including diagram (ML18289A580)

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: March 25, 2021By: _____
Magdalena R. Gryglak
Region 3